| [432] FAVORABLE CROSS-RESISTANCE PROFILE OF TWO NOVEL HEPATITIS C VIRUS INHIBITORS, SCH-503034 AND HCV-796, AND ENHANCED ANTI-REPLICON ACTIVITY MEDIATED BY THE COMBINED USE OF … AY Howe, R Ralston, R Chase, X Tong, A Skelton, M Flint, S Mullen, ... Journal of Hepatology, S165, 2007 | 7 | 2007 |
| [5] Purification and properties of rabbit reticulocyte initiation factor Co-EIF-1 A Dasgupta, A Das, R Roy, R Ralston, A Majumdar, NK Gupta Methods in enzymology 60, 53-61, 1979 | 7 | 1979 |
| [793] COMBINATION OF TWO HEPATITIS C VIRUS INHIBITORS, SCH 503034 AND NM107, PROVIDES ENHANCED ANTI-REPLICON ACTIVITY AND SUPPRESSES EMERGENCE OF RESISTANT REPLICONS R Ralston, V Bichko, R Chase, M LaColla, L Lallos, A Skelton, ... Journal of Hepatology, S298-S299, 2007 | 6 | 2007 |
| 1194 Sustained Virologic Response and Boceprevir Resistance-Associated Variants Observed in Patients Infected with HCV Genotpype 1A/1B when Treated with Boceprevir plus … C Brass, RJO Barnard, JA Howe, RA Ogert, R Ralston, N Boparai, ... Journal of Hepatology, S471-S472, 2011 | 14* | 2011 |
| 2016 long-term outcomes following combination treatment with boceprevir plus peg-intron/ribavirin (P/R) in patients with chronic hepatitis C, genotype 1 (CHC-G1) JM Vierling, R Ralston, EJ Lawitz, J McCone, S Gordon, D Pound, ... Journal of Hepatology, S470-S471, 2010 | 34 | 2010 |
| 65 CLONAL ANALYSIS OF MUTATIONS SELECTED IN THE HCV NS3 PROTEASE DOMAIN OF GENOTYPE 1 NON-RESPONDERS TREATED WITH BOCEPREVIR (SCH503034) S Susser, MW Welker, M Zettler, A Wohnsland, E Hughes, R Ralston, ... Journal of Hepatology 48, S29, 2008 | 23 | 2008 |
| 9 BOCEPREVIR RESISTANCE-ASSOCIATED VARIANTS (RAVS) ARE OBSERVED MORE FREQUENTLY IN HCV (GT1)-INFECTED PATIENTS WITH POOR RESPONSE TO PEGINTERFERON ALFA-2B/RIBAVIRIN S Zeuzem, RJ Barnard, JA Howe, RA Ogert, R Ralston, N Boparai, ... Journal of Hepatology, S4-S5, 2011 | 26 | 2011 |
| 967 PRECLINICAL CHARACTERIZATION OF SCH 900518, A NOVEL MECHANISM-BASED INHIBITOR OF HCV NS3 PROTEASE X Tong, A Arasappan, F Bennett, R Chase, B Feld, Z Guo, A Hart, ... Journal of Hepatology, S351, 2009 | 2 | 2009 |
| A peptide derived from hepatitis C virus E2 envelope protein inhibits a post-binding step in HCV entry R Liu, M Tewari, R Kong, R Zhang, P Ingravallo, R Ralston Antiviral research 86 (2), 172-179, 2010 | 26 | 2010 |
| Acute hepatotoxicity of oncolytic adenoviruses in mouse models is associated with expression of wild-type E1a and induction of TNF-α H Engler, T Machemer, J Philopena, SF Wen, E Quijano, M Ramachandra, ... Virology 328 (1), 52-61, 2004 | 60 | 2004 |
| AJRCMB Articles in Press. Published on May 30, 2003 as doi: 10.1165/rcmb. 2003-0028OC SP Umland, CG Garlisi, H Shah, Y Wan, J Zou, KE Devito, WM Huang, ... | | 2003 |
| Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies RJO Barnard, JA Howe, RA Ogert, S Zeuzem, F Poordad, SC Gordon, ... Virology 444 (1-2), 329-336, 2013 | 79 | 2013 |
| Antibodies to hepatitis C virus asialoglycoproteins R Ralston, F Marcus, K Thudium, B Gervase, J Hall, K Berger, QL Choo, ... US Patent App. 10/964,054, 2005 | 5 | 2005 |
| Antibodies to hepatitis C virus asialoglycoproteins RO Ralston, F Marcus, KB Thudium, BA Gervase, JA Hall, KM Berger, ... US Patent 7,105,303, 2006 | 44 | 2006 |
| Cell cycle-dependent disruption of E2F-p107 complexes by human papillomavirus type 16 E7 K Zerfass, LM Levy, C Cremonesi, F Ciccolini, P Jansen-Dürr, L Crawford, ... Journal of general virology 76 (7), 1815-1820, 1995 | 53 | 1995 |
| Cell lines for production of replication-defective adenovirus JA Howe, KN Wills, IRO Ralston, SJ Sherrill US Patent 7,851,218, 2010 | 12 | 2010 |
| Characterization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia viruses R Ralston, K Thudium, K Berger, C Kuo, B Gervase, J Hall, M Selby, ... Journal of virology 67 (11), 6753-6761, 1993 | 294 | 1993 |
| Characterization of resistance mutations against HCV ketoamide protease inhibitors X Tong, S Bogen, R Chase, V Girijavallabhan, Z Guo, FG Njoroge, ... Antiviral research 77 (3), 177-185, 2008 | 158 | 2008 |
| Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus–infected patients S Susser, C Welsch, Y Wang, M Zettler, FS Domingues, U Karey, ... Hepatology 50 (6), 1709-1718, 2009 | 397 | 2009 |
| Characterization of the hepatitis C virus E2/NS1 gene product expressed in mammalian cells RR Spaete, ME Rugroden, QL Choo, K Berger, K Crawford, C Kuo, ... Virology 188 (2), 819-830, 1992 | 177 | 1992 |
Michael HoughtonVerified email at ualberta.ca